ADCs of
Scroll down to read more

About Adcendo

Adcendo ApS is a Copenhagen-based biotech company dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the ADC approach to new levels through a focus on cancer-associated targets that are professional internalizers and allow for superior selectivity via highly preferential cancer expression.

Our name, Adcendo, reflects this strategy of targeting ADCs to specialized endocytic receptors.
Our first target, uPARAP/endo180, reflects these characteristics, providing an efficient entry point for an ADC type drug into target-positive cancer cells, working essentially as a drug internalization pump to further enhance a targeted effect.
Adcendo was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet by scientists Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen from The Finsen Laboratory, together with biotech entrepreneur Henrik Stage.
Adcendo has been part of BioInnovation Institute’s Creation House Program from mid 2019 until closing of series A financing in April 2021.

Meet adcendo


Michael Pehl

Michael Pehl joined ADCendo as Chief Executive Officer in June 2021. Michael has over 25 years of international biotechnology and oncology leadership experience in both the US and Europe.

Read more

Henrik Stage
Co-founder & CFO

Henrik Stage is an experienced biotech-entrepreneur, active in several biotech companies, and was previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014.

Read more

Christoffer Nielsen
PhD, Co-founder & COO

Christoffer F. Nielsen got his PhD in nanomedicine from the iNANO center at Aarhus University in 2012, having worked on development of methods for antibody-mediated delivery …

Read more

Scientific co-founders

Lars Henning Engelholm
PhD & Co-founder

Lars H. Engelholm got his PhD in biochemistry from University of Copenhagen in 2001, and today he is a group leader at The Finsen Laboratory. Already early in his career …

Read more

Niels Behrendt
PhD, DSc & Co-founder

Niels Behrendt is a Doctor of Science and PhD from the University of Copenhagen. He has been active in cancer research for more than 20 years and has particular expertise …

Read more

Team members

Jette Lange
PhD & Senior scientific project manager

Sander van Putten
PhD & Senior scientific project manager

Camilla Dall
MSc & Research Scientist

Ida Gregersen & Research Scientist

Christoffer Flyger & Student Helper

Board of Directors

John Haurum
M.D., D.Phil. & Chair

John Haurum is a Non-executive Director in European biotech companies: Adcendo, Agomab, CatalYm, Neophore, Storm, Synact, Synklino …

Read more

Jeroen Bakker
PhD – Novo

Jeroen Bakker is currently a Principal at Novo Holdings and is part of the Novo Seeds team focusing on company creation and early-stage financings …

Read more

Joël Jean-Mariet
PhD – Ysios Capital

Joël Jean-Mariet is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology in 2001 and was its CEO until it was …

Read more

Rez Halse
PhD – RA Capital

Rez Halse is a Partner, RA Ventures at RA Capital Management. Rez’s primary responsibility is to lead early-stage private investments in, and …

Read more

Mårten Steen
MD PhD – HealthCap

Mårten Steen is a partner of HealthCap. Previously, he has worked with business development at Merck Serono focusing on both product and technology …

Read more

Sanne de Jongh
MSc – Gilde Healthcare

Sanne de Jongh is Investment Manager at Gilde Healthcare, where she focuses on the firms’ investment activities in the biopharmaceutical sector. She …

Read more

Lars H. Engelholm
PhD – Founder director

Lars H. Engelholm got his PhD in biochemistry from University of Copenhagen in 2001, and today he is a group leader at The Finsen Laboratory. Already early …

Read more

Advisory board

John M. Lambert. PhD

Consultant/Scientific Advisor
Former CSO and executive at ImmunoGen
Honorary Professor, Queen’s University Belfast, Northern Ireland, UK.

Dr. John Lambert has a longstanding and well recognized history working in the ADC field. In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics, before joining ImmunoGen in 1987. After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016, followed by a year (2017) on the Executive Committee in an Emeritus capacity until retirement. During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla®, as well as numerous other ADCs taken into clinical development. One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in a phase 3 trial for the treatment of platinum-resistant ovarian cancer. In 2018, he was appointed as an Honorary Professor of Queen’s University Belfast, Northern Ireland, UK.

Murray Yule, MD

Murray Yule is a UK certified oncologist trained in Addenbrookes Hospital Cambridge and the Texas Medical Center with more than eighteen years experience in the pharma industry with the last ten years spent working in European Biotecnology companies. He has a deep experience in translational oncology and early stage clinical studies of novel biologics including ADCs in solid tumours through his experience at NBE Therapeutics and Axl directed therapies at ADC therapeutics.

Vincent de Groot, PhD, CLP

Dr. de Groot has a track record in creating and capturing value, as biotech entrepreneur, business development executive and transactor. His profile blends biotech entrepreneurship mentality with hands-on big pharma experience in licensing, acquisitions and venturing. Dr. de Groot founded and led the ADC company Syntarga from inception to exit (Trade Sale). Syntarga discovered and developed [vic-]trastuzumab duocarmazine (SYD985), an ADC drug candidate currently in Phase 3 clinical development.

Our Investors

Contact information

For all inquiries, please contact adcendo via the e-mail address